PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 51690
- Registration Number
- NCT03441633
- Locations
- 🇪🇸
IDIAP Jordi Gol, Barcelona, Cataluña, Spain
A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
- Conditions
- Dilated CardiomyopathyLamin A/C Gene Mutation
- Interventions
- Drug: ARRY-371797 (PF-07265803)Other: Placebo
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77
- Registration Number
- NCT03439514
- Locations
- 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇳🇴Oslo University Hospital, Rikshospitalet, Oslo, Norway
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3164
- Registration Number
- NCT03422822
- Locations
- 🇺🇸
Tilda Research Inc., Irvine, California, United States
🇺🇸Beach Allergy and Asthma Specialty Group, A Medical Corporation, Long Beach, California, United States
🇺🇸Center for Clinical Studies, LTD.LLP, Webster, Texas, United States
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Drug: PlaceboProcedure: HSCT
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 730
- Registration Number
- NCT03416179
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇵🇱WWCOiT im. M. Kopernika w Lodzi, Lodz, Poland
Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Biological: PF 06687234Biological: [124I]IB PF 06687234
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Pfizer
- Registration Number
- NCT03414788
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
- Conditions
- OnychomycosisTinea Unguium
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55
- Registration Number
- NCT03405818
- Locations
- 🇺🇸
Madera Family Medical Group, Madera, California, United States
🇺🇸MedStar Health Research Institute - MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Stanford University School of Medicine, Palo Alto, California, United States
A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: Epoetin Hospira MDVDrug: Epoetin Hospira SDV
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 68
- Registration Number
- NCT03398473
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
- Conditions
- mCRPC
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1054
- Registration Number
- NCT03395197
- Locations
- 🇧🇪
Clinique Saint-Pierre Ottignies, Ottignies, Belgium
🇧🇪CHU UCL Namur site Godinne, Yvoir, Belgium
🇧🇷Instituto Nacional de Câncer José de Alencar Gomes da Silva - INCA, Rio de Janeiro, RJ, Brazil
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 244
- Registration Number
- NCT03395184
- Locations
- 🇺🇦
Regional Municipal Non-profit Enterprise "Chernivtsi Regional Clinical Hospital", Surgery Department, Chernivtsi, Ukraine
🇺🇸Dothan Surgery Center, Dothan, Alabama, United States
🇺🇸Gut P.C., dba Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1459
- Registration Number
- NCT03387423
- Locations
- 🇩🇪
Private Practice Richter, Rostock, Germany
🇩🇪Private Practice, Templin, Germany
🇩🇪Private Praxis, Duesseldorf, Nordrhein-westfalen, Germany